Cost of innovation making fight against superbugs near impossible
Sander Flaum discusses the DISARM act and how we can fight back against antibiotic resistance.
Most recent articles by Sander Flaum
Don’t believe the bluster: Many Americans like their healthcare
Contrary to popular belief, most Americans like their healthcare and don’t want to change it.
Corporations are people – and they are beginning to act like it
CVS is pushing into primary care. If successful, might this prove that corporations can fulfill the Democratic dream of socialized health?
Amgen’s innovative osteoporosis drug is something we can all get behind
Sander Flaum is principal of Flaum Navigators.
Pharma can’t win with critics, even when it makes breakthroughs
Even when pharma produces breakthroughs, critics still find something or other to nitpick.
Continued research depends on fair prices for treatments
Sander Flaum explains why continued research depends on fair prices for treatments.
Why health insurers want to cast pharma as a villain
Sander Flaum takes a look at why health insurers want to cast pharma as the villain.
Focus on drugs’ cost may prevent their discovery
Breakthrough drugs will eventually be more affordable, but a misplaced focus on their cost may prevent them from being discovered at all.
Pharma must consider new approach to opioid crisis
As more and more people die from opioid overdoses, it’s time for pharma to own up to its collective responsibility and come up with a solution.
Should big pharma begin thinking a little smaller?
Big pharma should extend its vision beyond the blockbusters to make room for orphan drugs.
